What is CorWave?
CorWave is a medical technology company headquartered in Clichy, France, dedicated to developing advanced cardiac assist devices. The company's focus is on creating innovative solutions to address the significant unmet needs in treating heart failure. By leveraging cutting-edge engineering and biomedical expertise, CorWave aims to provide life-saving and life-enhancing technologies for patients suffering from severe cardiac conditions. Their work positions them at the forefront of cardiovascular innovation, seeking to improve patient outcomes and quality of life.
How much funding has CorWave raised?
CorWave has raised a total of $86.7M across 3 funding rounds:
Series A
$4M
Series B
$17.1M
Series C
$65.6M
Series A (2013): $4M with participation from G�rard Hasco�t
Series B (2016): $17.1M led by Bpifrance, Novo Seeds, Sofinnova Partners, Seventure Partners, and Ysios Capital
Series C (2023): $65.6M supported by Ysios Capital, Novo Holdings, Sofinnova Partners, Seventure Partners, Bpifrance, and EIC Fund
Key Investors in CorWave
Ysios Capital
Ysios Capital is a venture capital firm specializing in life sciences, focusing on highly innovative biotechnology companies worldwide to develop novel therapies for unmet medical needs.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, established in 1999 and headquartered in Hellerup, Denmark.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability, acting as a hands-on company builder across the entire value chain of life sciences investments.
What's next for CorWave?
With the recent major strategic investment, CorWave is poised for accelerated development and market penetration. This substantial capital infusion is expected to fuel further research and development, scale manufacturing capabilities, and support regulatory approval processes. The company's strategic financing indicates a strong market confidence in its technology and its potential to disrupt the cardiac device sector. CorWave's next steps will likely involve expanding its clinical trials, preparing for commercial launch, and solidifying its position as a key player in the global healthcare market.
See full CorWave company page
